Market Overview

Benzinga's Top #PreMarket Gainers

Share:
Related ALNY
Credit Suisse Bullish On Most Big Pharma Names
Alnylam Pharmaceuticals Dips Lower After Company Announces 2016 Pipeline Goals Towards 'Alnylam 2020'
Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2015 Results - Earnings Call Transcript (Seeking Alpha)
Related MRK
ALK Announces Merck Submits BLA to FDA for Investigational House Dust Mite SLIT-tablet
How To Invest In An Aging World With The 'Live Long & Prosper' ETF
S&P 500 Weekly Update: Should Investors Be Concerned? Yes. Panic? No. (Seeking Alpha)

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares jumped 35.93% to $90.00 in pre-market trading after the company reported that it has acquired investigational RNAi Therapeutic assets from Merck (NYSE: MRK). Genzyme and Alnylam expanded their collaboration on rare genetic diseases.

Beam (NYSE: BEAM) shares gained 25.93% to $84.35 in the pre-market after the company agreed to be acquired by Suntory Holdings for $83.50 per share in cash.

NII Holdings (NASDAQ: NIHD) surged 20.81% to $2.70 in the pre-market session after the company and Telefonica signed agreements to provide wholesale voice and data services to Nextel in Brazil and Mexico.

Clovis Oncology (NASDAQ: CLVS) soared 6.99% to $79.15 in the pre-market trading after the company announced 2014 objectives and financial outlook.

Posted-In: PreMarket GainersNews Pre-Market Outlook Markets Movers

 

Related Articles (ALNY + BEAM)

Get Benzinga's Newsletters